Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-949-7 | CAS number: 719-59-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Remarks:
- intravenous
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 996
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Principales of Good Laboratory Practice and the “Chemikaliengesetz” (Chemicals Act) of the Federal Republic of Germany
- Version / remarks:
- EEC Guide-Line 92/69/EEC, Annex I, dated 29th December 1992
- GLP compliance:
- yes
Test material
- Reference substance name:
- 2-amino-5-chlorobenzophenone
- EC Number:
- 211-949-7
- EC Name:
- 2-amino-5-chlorobenzophenone
- Cas Number:
- 719-59-5
- Molecular formula:
- C13H10ClNO
- IUPAC Name:
- (2-amino-5-chlorophenyl)(phenyl)methanone
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: Albino
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age at study initiation: male: 33 days, femals:35 days
Weight at study initiation: male: 26.6g±1.6, female: 24.2g±1.8
Fasting period before study: 16 to 20 hours before and up to 2 hours after administration
Housing: individual accommodation in type II Makroion cages with softwood granulate bedding
Diet (e.g. ad libitum): Flitered, demineralized water, adjusted to Ph=2.6±0.3 with hydrochloric acid, was freely available to the animals in bottles
Acclimation period: 7days
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- DMSO
- Details on exposure:
- The single intravenous administration was performed with a Hamilton syringe from Hamilton Bonaduz AG Typ Nr. 1710 TLL P/N: 81022/00, and a No.20 cannula, batch No. E592 802 from Beetan-Dickinsan into a tail vein.
The rate of injection was approx.. 0.1ml/sec
ADMINISTRATION VOLUME: 1ml/kg body weight.
The day of administration counted as day 1 for each treated animal - Doses:
- 25mg/kg
40mg/kg
60mg/kg - No. of animals per sex per dose:
- 5 animals/dose/sex
40 animals in total (20 males and 20 females) - Control animals:
- yes
- Details on study design:
- Duration of observation period following administration: 14 days
Frequency of observations: On the day of administration (day 1= day of the treatment) the animals were observed throughout the working day.
Thereafter, up to the 14th day, they were observed twice daily (in the morning and in the afternoon). On weekends and holidays, they were observed once daily (in the morning).
Weighing: All study animals were weighed one day before the study start (day -1 = fasting day) and before treatment. The surviving animals were weighed on the 8th and 15th study day.
Necropy of survivors performed: yes
Other examinations performed: All animals that died intercurrently were autopsied and examined macroscopically. The findings were recorded.
After a 14 day Observation period, the surviving animals were exsanguinated under deep Pentobarbital narcosis (40 mg/kg.s.c injection), autopsied and examined macroscopically.
Results and discussion
Effect levelsopen allclose all
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 49.1 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 41.1 mg/kg bw
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 45.2 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 34.7 - < 53.7
- Mortality:
- 12 of 40 treated animals died. Death occurred within 1 day after administration
- Clinical signs:
- After the administration of the test compound, the following symptoms were seen:
Males: 25mg/kg: Sternal or lateral recumbency, tachypnea, and tonic-clonic convulsions.
Males: 40mg/kg: Sternal or lateral recumbency, dyspnea, tachypnea, exophthalmia and tonic-clonic convulsions.
Males: 60mg/kg: Sternal or lateral recumbency, dyspnea, exophthalmia and tonic-clonic convulsions.
Females: 25mg/kg: Sternal or lateral recumbency, tachypnea, and tonic-clonic convulsions.
Females: 40mg/kg: Sternal or lateral recumbency, dyspnea, tachypnea, exophthalmia and tonic-clonic convulsions.
Females: 60mg/kg: Sternal or lateral recumbency, dyspnea, tachypnea, exophthalmia and tonic-clonic convulsions. - Body weight:
- The body weights of the animals were not influenced by the administration of the compound
- Gross pathology:
- No macroscopic organ or tissue findings at the autopsy of animals which died within 5min after administration were registered. One female animal which died within 1 day after administration of 60mg/kg b.w., showed macroscopically marked congestion of the liver.
At autopsy after an observation period of 2 weeks one animal showed congestion of the liver and one animal showed tail necrosis and loss of tailtip.
Any other information on results incl. tables
For the male animals the LD50 was estimated as 41.1mg/kg i.v (24h, 7 and 14 days) and for the female animals as 54.5mg/kg i.v (24h) and 49.1 mg/kg i.v (7 and 14 days). A common evaluation of both genders leg to an LD 50 of 47.2 mg/kg i.v and the 95% confidence interval (38.7-58.6]mg/kg i.v for the data observed 24h after application and to an LD 50 of 45.2mg/kg i.v and the 95% confidence interval [37.4-53.7]mg/kg i.v for the data observed 7 and 14 days after application.
Applicant's summary and conclusion
- Conclusions:
- The approx.. LD50 of 2-AMINO-5-CHLOROBENOPHENONE i.v. in OF1 mice is 45.2mg/kg for both gender (LD50 of 41.1 mg/kg b.w. for males and 49.2 mg/kg for females)
- Executive summary:
An acute toxicity study with 2-AMINO-5-CHLOROBENOPHENONE batch 043H3449, was performed in mice from 22.05.1996 to 05.06.1996.
The compound was dissolved in Dimethylsulfoxid solution and administered intravenously. Five males and five females per group were treated.
After administration of 25,40 and 60mg/kg (administration volume: 1ml/kg body weight: administration rate 0.1ml/sec) and an observation period of 14 days, the following toxicity data were established:
2-AMINO-5-CHLOROBENOPHENONE, approx. LD50 i.v. mouse
Male: 41.1mg/kg
Female:49.1mg/kg
Male+female: 45.2mg/kg
12 of 40 treated animals died Death occurred within 1 day after administration
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.